Blake Borgeson - Dec 12, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Director
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Dec 12, 2023
Transactions value $
-$84,693
Form type
4
Date filed
12/14/2023, 06:51 PM
Previous filing
Nov 30, 2023
Next filing
Dec 28, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Sale -$84.7K -11.4K -0.15% $7.40 7.38M Dec 12, 2023 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 18, 2023.
F2 The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $7.26 to $7.51 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.